OKYO Pharma Limited’s SEC filings document foreign-private-issuer reports on Form 6-K for a clinical-stage biopharmaceutical company with ordinary shares listed on Nasdaq. The disclosures cover urcosimod clinical and regulatory updates for neuropathic corneal pain, scientific-meeting materials, and descriptions of the company’s focus on inflammatory eye diseases and other ocular disorders.
The filing record also includes capital-structure and financing disclosures tied to Form F-3 registration statements, ordinary-share offerings, underwriter option exercises, and insider share purchases. These records present formal updates on the company’s securities, ownership activity, incorporated exhibits, and material announcements furnished under Exchange Act Rule 13a-16.
OKYO Pharma reported that Panetta Partners Limited, an entity in which Executive Chairman Gabriele Cerrone has a beneficial interest, acquired 210,000 of the company’s ordinary shares on NASDAQ. Following this purchase, his total holding is 10,382,677 shares. The news announcement was furnished as Exhibit 99.1 and is not deemed filed under Section 18 of the Exchange Act.
OKYO Pharma LTD has filed a Form 6-K to furnish a news announcement about the regulatory registration pathway and a planned 100-patient multi-center clinical trial of Urcosimod in neuropathic corneal pain. The company states that the announcement, dated September 22, 2025, is included as Exhibit 99.1 to the report. The furnished information is not deemed filed under the Securities Exchange Act and is not automatically incorporated into other securities law filings unless specifically referenced.
OKYO Pharma Limited filed an Amendment No. 1 to its Form 20-F for the fiscal year ended March 31, 2025 to correct an omission in the exhibits. The sole change is a revision of the Exhibit Table to include the Company’s Clawback Policy, which had been erroneously omitted from the original filing. The amendment states that no other disclosures were modified or updated and that subsequent events after the original filing are not reflected.
The filing confirms the registrant is incorporated in Guernsey, prepares financial statements under IFRS, is an emerging growth company, is listed on the NASDAQ Capital Market, and had 37,610,676 ordinary shares outstanding as of July 3, 2025. The company indicates it has filed required reports and submitted required interactive data files.